which could be a prime site for infections. Sorto hasn't had any infections there yet,
Andersen says.)Ideally, the implants would need to be wireless, but the amount of information coming out of the chips is so large,
Infections aren't the only worry. The chip is like a microscopic pincushion that's pushed into the brain,
if any are linked with potential genetic disorders. But until then Krawetz says the main goal is to automate RNA sequencing of sperm
#World's first malaria vaccine gets green light from European regulatory agency The world's first malaria vaccine has cleared its last major hurdle on its way to being approved for real-world use.
saying it is safe and effective to use in babies at risk for the parasitic disease.
It's not the only vaccine developed to fight malaria; an experimental malaria vaccine called Pfspz was found to be much more effective at preventing malaria infection.
Yet Mosquirix is the first to make it this far along in the approval process. Mosquirix helps to prevent infection from the Plasmodium falciparum, one of the deadlier malaria parasites.
The vaccine prompts the body to produce a higher amount of antibodies to stop the parasite from infecting the liver.
It's made specifically to combat infection in children and isn't intended for use in adults or travelers.
Early results of a clinical trial of Mosquirix showed that three doses of the vaccine could cut the risk of infection in half for children between between five and 17 months old.
For younger infants between six weeks and 12 weeks, infection was reduced by only 30 percent.
and children's chances of getting severe malaria or dying did not change at all. Some scientists are concerned that the potential costs associated with such a complex
Still, Africa is need in desperate for a malaria vaccine, even if it's only partially effective.
Malaria infection spread through the blood by mosquito bites kills upwards of 500 000 people each year.
Half the world's population live in areas at risk of infection.""This vaccine could mean children will have only two bouts of malaria a year instead of five,"Dr. Martin De Smet,
a malaria expert at Doctors Without Borders, told the Huffington Post. THE WHO must decide if that is justification enough to recommend Mosquirix to the public h
#Researchers engineered a protein factory inside a living cell for the first time For the first time, scientists have discovered what makes the cell tiny protein-making machines run
but infection can be avoided through routine hand-washing and by using gloves or other barriers that prevent contact with bodily fluids.
"The results of this interim analysis indicate that rvsv-ZEBOV might be highly efficacious and safe in preventing Ebola virus disease,
and disease tracking as likely early applications, but said the chip could also be used to power more immersive gaming experiences
Patients of varying disabilities have tested the arm at the lab and helped push the design forward.
#HPV Vaccine Is Effective Against Multiple Cancer-Causing Strains The human papillomavirus vaccine, Cervarix, not only has the potential to prevent cervical cancer,
it is also effective against other common cancer-causing stains, according to a recent study. Researchers found that Cervavix was effective aside from just the two HPV types, 16 and 18,
which are responsible for about 70 percent of all cases.""The study confirms that targeting young adolescent girls before sexual debut for prophylactic HPV vaccination has a substantial impact on the incidence of high grade cervical abnormalities,"researcher Dan Apter,
Director, said in a statement. Cervarix, not only has the potential to prevent cervical cancer, but was effective against other common cancer-causing human papillomaviruses, aside from just the two HPV types, 16 and 18,
which are responsible for about 70 percent of all cases. For the study, researchers collected and analyzed data from nearly 20,000 young women.
They found that the vaccine was extremely effective in young women who had never been infected with HPV.
including up to 100 percent of those with the immediate precursor grade to cancer. The women were followed for up to four years post-vaccination.
The study is the final report from the Papilloma Trial Against Cancer in Young Adults (PATRICIA), a multinational clinical trial encompassing 14 countries in Europe, the Asia-Pacific region
and the United states. While the trial did not investigate the vaccine's efficacy in males, sexually transmitted HPV causes anogenital and head and neck cancers in both males and females.
and neck cancers now number around 8, 400 in the United states, annually.""The more adolescents are vaccinated,
"Cervical cancer is the fourth most common cancer among women. In the United states, about 12,000 new cases,
and 4, 000 deaths occur annually, according to the SEER database of the National Cancer Institute.
These children, ages 5 and younger, die from preventable diseases such as pneumonia, dehydration, diarrhea, and systemic infections that could be treated with antibiotics.
Ninety-nine percent of them live in poor countries. Dr. Barry Finette, founder and CEO of Burlington-based THINKMD,
Fever, cough, diarrhea? Does your child have blueness around the mouth, coughing? Vomiting? If they are vomiting, how often?
"One doctor for 60,000 peoplethe challenge Finette faced as he contemplated making a dent in the overwhelming toll of disease on poor children was primarily a shortage of skilled healthcare professionals."
and hopefully increase understanding of disease in the long run. Many other devices have marked their presence for helping the people suffering from tremors like pen grips
It doesn cure the disease they still have tremor but it a very positive change.
suffer from tremors and Parkinson disease. Anupam Pathak, the founder of Lift Lab, appreciated the shift of a four-person startup in San francisco to the colossal Google campus in Mountain view which has encouraged them to enhance their creativity.
It is involved also in developing a contact lens for measuring glucose levels in tears for diabetics
and researching the role of nanoparticles in blood in diseases detection. Clinical trials have revealed that the spoon reduces shaking by about 76 percent.
I didn't know anyone with a peanut allergy. At school peanut butter and jam sandwiches were standard fare for lunches.
#After Celgene Deal, Juno Revs Armored CAR For Ovarian Cancer Trial Juno Therapeutics has built remarkable momentumncluding last week much-dissected $1 billion deal with Celgenepon
early success treating leukemia and lymphoma patients with a first generation of experimental T cell therapies developed by its academic partners.
Now, with one of those partners, Seattle-based Juno (NASDAQ: JUNO) is about to start another landmark trial:
engineered to become better cancer killers, and reinserted into the patient. CAR stands for chimeric antigen receptor,
an upcoming Phase 1 trial will treat patients with relapsed ovarian cancer, one of many solid-tissue tumors that are expected to be a much higher hurdle for the field of cell-based immunotherapy.
Though T cells still have much left to prove in blood-borne cancers, which are relatively rare,
scientists want to use the technology to target a cancer like ovarian, which will kill an estimated 14,000 women in the U s. this year. he big question is, an you cross over to solid tumors?'
'says Renier Brentjens, the director of cellular therapeutics at Memorial Sloan Kettering Cancer Center in New york and a Juno scientific founder.
Brentjens will begin to answer his own question soon. He tells Xconomy that in August
or September he will begin treating ovarian cancer patients with armored CAR-T cells, engineered to send out a chemical signal that recruits the patientsnon-engineered T cells to come join the attack. ee going full force forward,
says Brentjens. That extra boost is one of three main modifications. The cells will also zero in on a tumor cell target called MUC16
and they will carry a self-destruction switch that clinicians can trigger in case the cells get too aggressive, hit unintended targets,
Those modifications are meant to overcome some of the challenges solid tumors present, although Brentjens cautions not to expect the same results that CAR-T cells have shown so far in leukemia and lymphomaemission rates well above 50 percent.
Just as it did with some of the blood-cancer programs now under Juno roof, Sloan Kettering will run the trial.
Juno has license to the technology, says Juno chief financial officer Steve Harr. The trial is important on two fronts.
T cell therapies have treated relatively rare blood-borne cancers. If that the extent of the treatment reach,
and patients dream of the cells attacking solid tumors, which account for about 90 percent of all cancers.
The American Cancer Society estimates that ovarian cancer is the fifth-deadliest in the U s. he animal data have been compelling,
and we want to get this into patients, says Harr. The Sloan Kettering trial won be the first test of engineered T cells in solid tumors.
In a tiny six-person study reported in April, CAR-T cells from the University of Pennsylvania appeared to be safe.
NVS), reported the cells showed no effect on the tumors. And Juno partner, Seattle Children Hospital, has started just a Phase 1 CAR-T trial for children with neuroblastoma,
a cancer that develops from immature nerve cells. In the case of Brentjens cells, the protein that signals to other T cells to help with the attack, could be the difference.
Brentjens says by restricting the secretion of IL-12 to the area right around the tumor,
In an earlier CAR-T trial at Sloan Kettering, to treat non-Hodgkin lymphoma, two patients suffered a cytokine storm
For example, people with a lot of tumor mass in their bodies might need to be monitored more closely.
Researchers at the University of California, Los angeles published work late last year that showed why certain patients responded well to a different kind of cancer immunotherapyn antibody called pembrolizumab (Keytruda.
customisable system other researchers and technologists can use to benefit those who have motor neuron diseases (MND) and quadriplegia.
< Back - Next >
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011